RE:Lets have some Valuation fun...More valuation fun with MCNA Beech... Obviously a $30 CDN valuation is quite the stretch with everything going perfectly, but isn't it fair to say that there is also quite a lot of additional value in whoever takes over the MCNA platform? As you noted, your valuation does not even include any off label use, no EU, No South America, no Asia, and no pre-existing BC patients.
But don't forget at least two other important valuation possibilities that could net a pursuer an incredible money cow with MCNA down the road. One is that MCNA is quite likely effective with other cancers as well. Secondly, is the incredible significance of MCNA being (apparently at this point) able to restore the immune systems back to peak performance in dogs in just 24 hours after MCNA treatment in subjects that had just been treated with chemo-radiation and had their immune systems thouroughly compromised. Those immune systems take weeks to recover under curent treatment regimens. There is already quite a bit of proof that this works when administered to dogs if I remember correctly. Off hand, I can't remember the name of the MCNA platform drug Bioniche developed and used on dogs for that purpose, but it would just be a few human trials away from seeing if this success carries over to human applications.
Can you imagine the value of this immune system application if it comes to fruition? That application would be utilized for every patient getting chemo. The market would be completely mind blowing should that come to pass. There has to be significant additional value associated with the MCNA platform for other drug developments beyond this one bladder cancer application I would think. I don't think this platform is a one trick pony by any means...